PDA Development for Oropharynx Cancer | 167 6 Conclusion We developed a Dutch multidisciplinary patient decision aid focusing on treatment decisions for oropharyngeal tumors for whom primary transoral (robotic) surgery could be a curative treatment, following the quality criteria of IPDAS36. This web-based tool has shown to be feasible and an addition for regular counseling, as assessed by clinicians and OPSCC survivors. To this end, a multicenter trial has started in 2022 comparing regular care to patients receiving the PDA (www.kanker.nl, trial 1339) to investigate the effect of using a PDA in daily practice on patient knowledge and decisional conflict. Results are expected in 2026. Acknowledgements: The Dutch Patient Society, dr. Karssemakers, prof. Smeele, prof. Takes, dr. Van den Hoek, dr. Van Weert, dr. Navran, dr. Hamming, dr. Doornaert, dr. Vergeer, Latenstein (MSc), and Paul Alders (www.eyespirations.com)
RkJQdWJsaXNoZXIy MTk4NDMw